Making more of prostate biopsies
Poster Session 49

Aims and objectives of this presentation
To address the role of prostatic biopsies in the diagnosis of early prostate cancer, how to make use of their diagnostic and prognostic value in clinical decision making, and how to improve their diagnostic yield.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

608 Needle disinfectant technique during prostate biopsy is associated with less infection-related hospitalization: Results from a surgical collaborative
By: Ghani K.1, Auffenberg G.1, Brachulis A.1, Linsell S.1, Gao Y.1, Ye Z.1, Kraklau D.2, Montie J.1, Miller D.1
Institutes:1 University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 2 Lakeland Health, Dept. of Urology, St Joseph, United States of America

609 Are all pathologic Gleason scores 8 created equal? Implications for the applicability of new prostate cancer grading system
By: Gandaglia G.1, Fossati N.2, Bianchi M.3, Freschi M.4, Doglioni C.4, Farina E.2, Gallina A.2, Stabile A.2, Capitanio U.2, Salonia A.2, Montorsi F.2, Briganti A.2
Institutes:1 IRCCS Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 4IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy

610 Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy
By: Qi R., Moul J.
Institutes:Duke University Medical Center, Dept. of Urologic Surgery and Duke Cancer Institute, Durham, United States of America

611 Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy
By: Kweldam G.F.1, Kümerlin I.P.1, Nieboer D.2, Verhoef E.I.1, Steyerberg E.W.2, Van Der Kwast T.H.3, Roobol M.J.4, Van Leenders G. J. L. H.1
Institutes:1 Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, 3University Health Network, Laboratory Medicine Program, Toronto, Canada, 4Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands

613 An improved clinical risk stratification system to better predict cancer specific mortality at diagnosis in primary non-metastatic prostate cancer
By: Gnanapragasam V.1, Lophatananon A.2, Muir K.3, Gavin A.4, Wright K.5, Greenberg D.5
Institutes:1 University of Cambridge, Dept. of Academic Urology, Cambridge, United Kingdom, 2University of Warwick, Dept. of Health Science, Warwick, United Kingdom, 3University of Manchester, Dept. of Public Health, Manchester, United Kingdom, 4Queen’s University Belfast, Northern Ireland Cancer Registry, Belfast, United Kingdom, 5Public Health England, Cambridge, United Kingdom
Morphological and molecular pathway-based analysis of Gleason score 7 prostate cancer using a 17-gene expression assay

By: Bonham M.¹, McCullough D.², Lu R.³, Bennet J.³, Febbo P.⁴, Tsiatis A.⁵

Institutes: ¹Genomic Health, Dept of Pathology, Redwood City, United States of America, ²Genomic Health, Dept of Biostatistics, Redwood City, United States of America, ³Genomic Health, Dept. of Data Management, Redwood City, United States of America, ⁴Genomic Health, Dept. of Translational Sciences, Redwood City, United States of America, ⁵Genomic Health, Dept. of Pathology, Redwood City, United States of America

Pathological outcomes after radical prostatectomy in men eligible for active surveillance, multi-institutional study

By: Mizuno K.¹, Inoue T.², Kinoshita H.³, Yano T.⁴, Kawanishi H.⁵, Kanda H.⁶, Terada N.⁷, Kamba T.², Okumura K.⁸, Kawakita M.⁹, Ogura K.¹, Sugimura Y.⁶, Matsuda T.³, Ogawa O.²

Institutes: ¹Japanese Red Cross Otsu Hospital, Dept. of Urology, Otsu, Japan, ²Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, ³Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, ⁴Kobe Medical Center General Hospital, Dept. of Urology, Kobe, Japan, ⁵Tenri Hospital, Dept. of Urology, Tenri, Japan, ⁶Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan

Routine use of magnetic resonance imaging in prostate cancer facilitates better candidate selection for active surveillance


Institutes: Institute Mutualiste Montsouris, Dept. of Urology, Paris, France

The value of PSA density in combination with PI-RADS scoring for prostate cancer prediction

By: Distler F.¹, Radtke J.P.¹, Bonekamp D.², Roethke M.³, Schiemmer H-P.², Roth W.², Hohenfellner M.¹, Hadaschik B.A.¹

Institutes: ¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Heidelberg, Dept. of Radiology, Heidelberg, Germany, ³University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany

Impact of targeted prostate biopsy using magnetic resonance imaging – ultrasound elastic fusion in men with suspicion of prostate cancer

By: Fourcade A.¹, Perrouin-Verbe M-A.¹, Tissot V.², Serey-Effeil S.¹, Callerot P.¹, Cuvelier G.³, Coquet J-B.⁴, Doucet L.⁵, Delage F.⁶, Deruelle C.⁴, Joulin V.⁴, Fournier G.⁴, Valéri A.⁴

Institutes: ¹University Hospital Of Brest, Department of Urology, Brest, France, ²University Hospital Of Brest, Department of Radiology, Brest, France, ³Hospital of Quimper, Department of Urology, Brest, France, ⁴University Hospital Of Brest, Department of Urology, Brest, France, ⁵University Hospital Of Brest, Department of Anatomato-Pathology, Brest, France

A non-inferiority multicentric controlled trial comparing three MRI-TRUS targeted biopsies to systematic TRUS biopsies for the detection of prostate cancer in patients with a single suspicious focus on prostate MRI: Results of the MURIELLE study

By: Delongchamps N.B.¹, Portalez D.², Bruguère E.³, Escourrou C.¹, Casanova J.M.⁴, Roumigué M.⁵, Hohn N.⁶, Bratan F.³, Sanzalone T.⁷, Rouvrière O.⁷, Fiard G.⁶, Thoulouzan M.⁵, Malavaud B.⁵, Bordier B.³, Guillotreau J.³, Bouazza N.¹, De Gorski M.², Mozer P.³, Aziza R.³, Renard-Penna R.³, Misrai V.³, Descotes J.L.⁶, Cornud F.¹

Institutes: ¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²Rangueil University Hospital, Dept. of Radiology, Toulouse, France, ³Clinique Pasteur, Dept. of Urology, Toulouse, France, ⁴Clinique Saint Jean de Dieu, Dept. of Urology, Paris, France, ⁵Rangueil University Hospital, Dept. of Urology, Toulouse, France, ⁶Grenoble University Hospital, Dept. of Urology, Grenoble, France, ⁷Hospices Civils de Lyon, Edouard Herriot Hospital, University Lyon 1, Dept. of Urinary and Vascular Radiology, Lyon, France, ⁸Pitié Salpêtrière University Hospital, Pierre et Marie Curie University, Dept. of Urology, Paris, France, ⁹Institut Universitaire du Cancer de Toulouse – Oncopole, Dept. of Urology, Toulouse, France
Summary and context
G. Van Leenders, Rotterdam (NL)